Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase-II Trial: AdrenoMedullin for Ischemic Stroke Study

Acute ischemic stroke (IS) is a devastating disorder closely linking to severe disabilities and poor quality of life. Currently, the only approved treatments are antiplatelet agents and reperfusion therapies; identifying other therapeutic options is necessary and urgent.1 After the onset of blood vessel occlusion, ischemic injury triggers inflammatory cascades in the parenchyma that further amplify tissue damage,2,3 implying the necessity of anti-inflammatory treatment from the very acute phase of IS.

Source: Journal of Stroke and Cerebrovascular Diseases - April 1, 2021 Category: Neurology Authors: Takeshi Yoshimoto, Satoshi Saito, Katsuhiro Omae, Yorito Hattori, Kazuki Fukuma, Kazuo Kitamura, Ryosuke Kakuta, Toshihiro Kita, Hirofumi Maruyama, Haruko Yamamoto, Masafumi Ihara Source Type: research